The main indications for nebulized antibiotic use are as maintenance therapy for patients with chronic Pseudomonas aeruginosa infection and in treatment protocols aimed at eradicating early P. aeruginosa infection. Daily nebulized antibiotic therapy has been used extensively in Europe for the last 25 years and recently in North America following the introduction of tobramycin solution for inhalation (TSI). The antibiotic is delivered directly to the site of infection, maximizing its efficacy and reducing its potential for toxicity. The efficacy of nebulized antibiotic therapy has been confirmed by meta-analyses of early studies which usually involved only small numbers of patients, and recently by large scale randomized control trials. These studies have shown that regular aerosolized antibiotic treatment results in improved respiratory function, less hospital admissions and respiratory exacerbations, and a significant reduction in the load of P. aeruginosa respiratory tract infection. Concerns about increasing bacterial resistance do not yet seem to have had any clinical impact. Successful eradication of early P. aeruginosa infection has been reported with nebulized colistin (in combination with oral ciprofloxacin), tobramycin and TSI. No advantage has been shown in studies comparing nebulized and intravenous antibiotics versus intravenous antibiotics alone in the treatment of acute respiratory exacerbations. Inhalation of antibiotics may provoke bronchospasm and patients should be assessed before and after treatment prior to continuing long-term therapy at home. Chronic Respiratory Disease 2005; 2: [35] [36] [37] [38] [39] [40] [41] 
Introduction
The potential benefits of aerosol therapies, including antibiotics, in cystic fibrosis (CF) have been discussed for over 30 years. 1 In 1974 Taussig wrote, 'The final critical evaluation of... aerosol therapy in cystic fibrosis must come from well-controlled clinical studies utilising sensitive and reproducible pulmonary fimction tests and clinical assessmen'.2 Nebulized antibiotic therapy has been used extensively in the UK since the early 1980s but has only recently been supported by evidence-based research. 3 The two main indications for using nebulized antibiotics in CF care are as maintenance therapy for patients with chronic Pseudomonas aeruginosa infection, and in treatment regimens directed at eradicating early P. aeruginosa infection. 4 Nebulized antibiotics may also be used in some centres as ancillary treatment to intravenous antibiotics for the management of respiratory exacerbations, as preferred therapy for multiresistant P.aeruginosa,5 and as part of eradication regimens for early Burkholderia cepacia complex (Bcc) infections. 6 Aerosol gentamicin administration has also been suggested for prophylaxis of P. aeruginosa infection. 7 The strength of the evidence for the use of nebulized antibiotics in these varied clinical situations varies from strong to weak to none. Patients with CF and chronic P. aeruginosa infection have a worse prognosis than those with intermittent or no P. aeruginosa infection.8 '9 It is the most frequently found pathogen in the CF lung, a major aetiologic factor in the progressive pulmonary damage which characterizes the disease, and is responsible for most of the respiratory related morbidity and mortality. There is a heightened inflammatory activity at the centre of CF lung disease that is fuelled by P. aeruginosa and its toxins. 10 The patient may be caught in a spiralling downward cycle in which inflammatory damage weakens the lung defences and abets the onset or progression of P. aeruginosa infection. The latter in turn exacerbates the inflammatory response.
The aim of daily nebulized antibiotic therapy is to prevent the onset of chronic P. aeruginosa infection (short-term administration), or to reduce the intensity of established infection (long-term administration). The simple hypothesis is that delivering the antibiotic directly to the site of infection will optimize its efficacy. High local antibiotic concentrations are needed to overcome biological antagonism in the sputum. The altered ionic environment in the CF lung interferes with drug accumulation by the bacteria, and extracellular neutrophil DNA may bind significant amounts of aminoglycosides.1 1 One study has suggested that a reliable bactericidal effect will only be achieved with concentrations 25 times the minimum inhibitory concentration (MIC). 12 Intravenously administered antibiotics achieve only about 12% of the peak serum concentration in the sputum.'3'15 High sputum drug concentrations cannot be achieved by the intravenous route without an unacceptable risk of toxicity. 16'17 Aerosol administration can deliver bactericidal drug concentrations to the site of endobronchial infection and with minimal absorption there is low risk of ototoxic or nephrotoxic effects. There seems to be no relationship between total pulmonary antibiotic deposition and lung damage, although with greater lung damage less of the antibiotic reaches the lung periphery.18 Studies by Hodson et al. 19 (1981) , Littlewood et al. 20 (1985) and
Valerius et al. 21(1991) , form the foundations for the use of nebulized antibiotics in the treatment of chronic and early P. aeruginosa infection. A multicentre, double-blind, placebo controlled trial of aerosolized tobramycin overcame some of the limitations of these studies. 25 Tobramycin solution for inhalation (TSI) is a nonpyrogenic, preservative free, pH adjusted formulation. Seventy-one patients received half strength physiological saline or 600 mg TSI in 30 mL half strength saline delivered by ultrasonic nebulizer. The drug dose was chosen to maximize efficacy by reaching sputum concentrations of at least 400 Lg/g, 10-fold the MIC of tobramycin susceptible P. aeruginosa and sufficient to overcome the competitive binding of tobramycin by CF sputum.1'12 Group 1 received active treatment for 28 days and placebo for 56 days, and group 2 received tobramycin for 56 days followed by placebo for 28 days. Differences in taste were masked by the addition of quinine to placebo and drug preparations. Serum creatinine concentrations, urine analysis, auditory acuity and vestibular function tests were used to monitor toxicity, and urine quinine concentrations were measured to monitor adherence. Sixty-six patients completed the trial. At 28 days in the TSI compared to placebo treatment periods there was a significant difference in respiratory function. FEVy increased by 3.7% predicted in the former and fell by 5.9% in the latter (P < 0.00 1). At the end of the three month trial the difference was 4.3% predicted, but still significant (P = 0.002). This may have reflected a greater use of oral and intravenous antibiotics in the placebo period (P = 0.006). TSI also reduced the sputum density of P. aeruginosa 100-fold during the first 28 days of treatment (P < 0.001) and the frequency of acute respiratory exacerbations (P = 0.06). No toxic effects were documented. The ultrasonic nebulizer, however, was cumbersome and disliked by patients. The 600 mg dose was expensive and not necessary to achieve adequate sputum drug concentrations.28 ' Touw et al. analysed all published articles between 1965 and 1995 concerning the inhalation of antibiotics in patients with CF.33 Most studies showed a reduction in hospital admissions and an improvement in lung function. There was no renal or ototoxicity. Introduction or selection of resistant bacteria was unusual and mostly transient, but some studies did report up to a 27, 28 30% resistance rate.
Nebulized antibiotics for maintenance therapy
In their meta-analysis (1996) ofthe benefits and risks of nebulized antibiotic delivery in CF, Mukhopadhyay et al. rejected nine of 14 trials because they did not randomize patients properly or failed to adequately describe outcome measures.22 These were defined in the meta-analysis as the number of acute pulmonary exacerbations, alterations in respiratory function, pseudomonas respiratory load, the number of patients with resistant P. aeruginosa, and the incidence of auditory, renal or respiratory adverse events. 22 The five remaining studies showed that nebulized antibiotic treatments significantly reduced the load of P. aeruginosa respiratory tract infection and the number of respiratory exacerbations requiring intravenous antibiotic treatment. Lung function was also significantly increased. The only concern was an increase in in vitro bacterial resistance to the administered nebulized drug that only narrowly failed to achieve significance. Other side effects were mild chest tightness and a bad taste in the mouth but there were no reports of disturbed renaj or auditory function.
Subsequent to Mukhopadhyay et al.'s meta-analysis the results of two phase III multicentre, randomized, double blind studies of TSI 300 mg compared to a quinine based placebo, each administered twice daily, were published.3 The 300 mg dose has more than 90% probability of realizing a peak sputum concentration at least 25-fold greater than the maximal MIC of the patients' P. aeruginosa isolates.32 Inclusion criteria specified age greater than six years, FEV1 between 25 and 75% predicted, and infection with P. aeruginosa but not Bcc. Patients received three treatment cycles of 28 days of nebulized therapy followed by 28 days off the trial medication, over a 168 day period. There were three main reasons for the on-off dosage schedule; 1) some treatment effect persisted at 28 days after stopping treatment; 2) animal toxicology studies showed reversal of tobramycin induced histological changes within 28 days of stopping treatment; and 3) the month off might minimize the development of bacterial tobramycin resistance and increase patient adherence. Randomization was designed to ensure a balance between active and placebo groups for age, disease severity, sputum production, centre, concomitant therapy with nebulized recombinant human deoxyribonuclease (Pulmozyme; Roche Products Limited, Welwyn Garden City, Herts, UK), and the MIC of P. aeruginosa sensitive to tobramycin. The treatment effect was defined as the mean relative change with active treatment minus the mean relative change with placebo from baseline at the end of the third cycle. Over 80% of 491 patients completed the trial.
After the first cycle the treatmnent effect for FEV, was about 12% (P < 0.001) and was maintained throughout the study. Colony forming units per gram of sputum fell significantly (P < 0.001). Patients in the TSI group needed fewer hospital admissions and less intravenous antibiotic treatments (P < 0.014), a difference apparent from four weeks. The positive treatment effect was seen in all subgroups analysed, stratified by age, gender, disease severity and patients established on treatment with Pulmozyme. An agestratified analysis of the effects of treatment on respiratory function showed a highly significant improvement in adolescents, greater than seen in any other age subgroup. TSI use was associated with improved global ratings of health related quality of life by patients, parents and physicians. 34 Sputum tobramycin concentrations were not significantly affected by patient age, gender or disease severity. Almost all patients had sputum concentrations at least 10 times their MIC and 95% had concentrations more than 25 times their MIC. 35 The systemic bioavailability of aerosolized TSI was measured at 11.7% without serum tobramycin accumulation over a 20-week study period. 35 Mukhopadhyay et al. revisited the subject of nebulized antibiotic treatments in CF in their Cochrane Review, updated in 2003.23 Eleven of 33 trials met the inclusion criteria of four weeks or more of treatment, randomized allocation to treatment, and a placebo or no placebo control group, or another nebulized antibiotic as a comparator. Despite important heterogeneity in these trials, and seven being of crossover design, the reviewers found evidence that nebulized antibiotics improved lung function and reduced the frequency of respiratory exacerbations. There was no evidence of clinically important adverse events. Though supporting this treatment modality the review cautioned against extrapolating to long-term conclusions about length and quality of life from the data. Eight trials were only one to six months long and the longest trials were described as of poor quality.
Tobramycin and colistin are the two most frequently prescribed antibiotics for aerosol delivery in CF care. The Cochrane Review found insufficient evidence to claim superiority for either but Hodson et al. have since reported a direct comparison of the two. 36 One hundred and fifteen patients with P. aeruginosa infection, age six years or older, with FEVy 25% predicted or more were randomized to receive either TSI 300 mg or colistin 80 mg (1 MU) twice daily for four weeks. There was a significant increase in FEV1 % predicted of 6.7% compared to a nonsignificant change of 0.37% in the TSI and colistin treated groups respectively. More physicians rated patients as improved, and more patients felt better, after TSI than after colistin treatment. Both treatments significantly decreased sputum P. aeruginosa density. In this shortterm study no patients were newly infected with Bcc or Stenotrophomonas maltophilia and there was no significant increase in bacterial resistance to the administered drugs. There were no clinically important adverse events.
This study suggests that nebulized TSI is superior to colistin in the treatment of patients with chronic P. aeruginosa infection but the findings should be interpreted with some caution. The study was not double-blind. The patients knew that TSI was a novel treatment and this may have introduced a bias. The majority of patients had received colistin in the preceding six months but were naive to TSI and therefore more likely to show improvements in respiratory function with the latter. There is no proven optimal dose for colistin but many centres use twice the dose administered in the study. The authors' sensibly conclude only that their study supports the use of TSI in patients not showing improvement (or stability) with conventional therapy including colistin.
Long-term safety and efficacy of TSI have been assessed in a 96-week study in 242 patients over six years of age with FEVy percent-predicted values between 25% and 75% normal.37 Adverse events were few and tended to decrease with increasing TSI exposure. More placebo than TSI treated patients reported vomiting, fever, abdominal pain and anorexia. Significantly more TSI treated patients reported mild to moderate voice alteration and tinnitus. The frequency of the latter did not exceed 3.5% and most episodes were mild and transient. No objective hearing loss was documented. Renal function, monitored by serum creatinine levels, showed no clinically significant changes with treatment. Gram-negative organisms intrinsicallyresistanttotobramycin, (Bcc, S. maltophilia, Achromobacter xylosoxidans), were not isolated any more frequently than in the placebo group, although there was an increase in the incidence of isolation of the fungus Aspergillus. The clinical significance of this is uncertain. These longer-term results were consistent with the effect of inhaled TSI on the respiratory microbial flora seen in the initial threetreatment cycle study. 38 Efficacy outcome measures showed that compared to the placebo group in the initial 24-week study, TSI treated patients needed fewer hospital admissions, and showed a 20 to 25% reduction in intravenous antibiotic use, and about a 33% reduction in oral quinolone use. After 96 weeks treatment mean FEV1 % predicted was maintained at 4.7% above baseline. Analysis ofthe subgroup of adolescent patients, who showed especially significant gains in lung function in Ramsey's study,3 after 24 months treatment with TSI in follow-on, open-label trials showed FEVy % predicted 14% above that at baseline. 39 Changes in MIC values in the adolescent group were consistent with those seen in the whole patient population. At 24 months the proportion of isolates with MIC 16 tg/mL or more had increased from 5 to 19% and the MIC90 had increased from 8 to 32 [Lg/mL. However, for the whole patient population and the adolescent subgroup there was no relationship between the proportion of patients responding to TSI inhalation, or the magnitude of the response, and the tobramycin MIC. Moss argues that concern about increased pseudomonal tobramycin resistance with TSI treatment is outweighed by the improvement in lung function and that the continued positive response, even in patients with resistant strains, suggests that the traditional parenteral breakpoint is not applicable to inhaled regimens.39 This may not reassure the physician concerned about resistance to intravenously administered tobramycin.
Nebulized antibiotics use in eradication regimens for early P. aeruginosa infection
The second major use of nebulized antibiotics in CF care is in eradication regimens for early P. aeruginosa infection. In 1985, Littlewood et al. reported experience of nebulized colistin 500 000 units twice daily in young children soon after pseudomonas was first isolated.2 Treatment reduced both the number of pseudomonas organisms isolated and the frequency of isolation from the respiratory tract. This innovative practice was advanced by Valerius et al. 21 Patients without any history of P. aeruginosa infection were randomly allocated to three weeks of nebulized colistin (106 IU) and oral ciprofloxacin (250-750 mg) each twice daily, or no additional treatment, whenever P. aeruginosa was isolated from routine sputum cultures during a 27-month trial. Chronic infection and the frequency of P. aeruginosa isolates were significantly less in the treated group (P < 0.05 and P = 0.0006, respectively). There were no serious adverse events. This study was the first to show that chronic infection with P. aeruginosa could be prevented. The same group refined their treatment protocol with further experience, reporting better results with three months high dose treatment with colistin inhalation and oral ciprofloxacin and an approximate 80% success rate. Other eradication regimens are equally effective. Inhalation of tobramycin 80 mg twice daily for 12 months prevented chronic Nebulized antibiotic therapy SP Conway 39 P. aeruginosa infection in 14 of 15 patients after one year of follow_up.4' A double-blind, placebo controlled, multicentre randomized trial of TSI 300 mg twice daily for 28 days in children under six years of age, and with baseline bronchoalveolar culture positive for P. aeruginosa, was stopped early because of evidence of a significant microbiological treatment effect.42 Bronchoalveolar lavage was performed at baseline and at 28 days. P. aeruginosa was found in none of the eight children in the active treatment group at 28 days but in 12 of 13 children in the placebo group. There was no renal toxicity, ototoxicity or significant bronchospasm associated with treatment.
Other uses of nebulized antibiotics in CF Nebulized antibiotic regimens have been studied in other clinical situations in CF care without clarity of effect. There was no clinical benefit from the addition of nebulized tobramycin to intravenous ticarcillin and tobramycin in the treatnent of acute respiratory exacerbations,43 but a significantly greater temporary eradication of P. aeruginosa in the treatment group (P = 0.03). Similar results were reported by Schaad et al. for inhaled amikacin.44 In a retrospective and uncontrolled study, Semsarin reported inconclusive results for the use of nebulized tobramycin in acute exacerbations. 45 The effects of inhaled gentamicin twice daily as prophylaxis against P. aeruginosa acquisition was studied in 28 children between one and 14 months of age at entry and defined as at special risk.7 None of the 12 patients who continued treatment uninterrupted for a mean of 78 months acquired P. aeruginosa infection compared to seven of 16 who stopped treatment after a mean 41 months (P = 0.01). The perceived advantages from treatment in this pilot study must be set against the potential toxicity of treatment, the negative effects on family functioning of a time consuming process, and the ability to prevent P. aeruginosa infection in the majority of children with other less invasive management protocols. 46 Nebulized TSI may be effective in the treatment of multiresistant P. aeruginosa because of the high sputum concentrations achieved.47'48 Combination therapy with an intravenous antibiotic such as meropenem, tazocin or ciprofloxacin is recommended.
Nebulized TSI for three consecutive months has been used as part of a treatment regimen that successfully eradicated early B. multivorans infection,6 but prospective studies are needed to confirm its efficacy in this situation.
Toxicity issues
Over the last several years increasing numbers of patients have been prescribed long-term nebulized antibiotics. We should continue to monitor the safety of this now standard therapy. In Hodson's early study the authors reported anecdotal experience of a patient treated for three years with nebulized antibiotics.19 No drug resistant organisms developed but because of this theoretical danger treatment was not recommended for patients still fit enough to lead active, normal lives but only for those with chronic P. aeruginosa infection showing deterioration in lung function or requiring frequent courses of intravenous antibiotic therapy. Subsequent studies have shown increasing MIC levels with nebulization of TSI, but no adverse clinical consequences. Future widespread resistance to intravenous tobramycin may be a major clinical difficulty.
Bronchoconstriction after either inhaled colistin or tobramycin is a common acute event and should be actively looked for before regular nebulized antibiotic administration. Patients may respond to concurrent or predosing with salbutamol. [49] [50] [51] [52] Clinicians should not dismiss the possibility of toxic serum aminoglycoside concentrations resulting from nebulized drug delivery, especially if used in conjunction with intravenous administration of the same antibiotic. Hoffinann et al. reported acute renal failure in a 20-year old after one week's treatment with TSI 300 mg twice daily. 53 Although the patient was also prescribed ciprofloxacin, measurable serum tobramycin levels 24 hours after the last inhaled dose and renal biopsy findings consistent with aminoglycoside induced changes suggested a cause effect relationship between inhalation of TSI and the acute renal damage. The little research in this area shows a range of systemic absorption that may reflect individual patient differences and is almost certainly unpredictable. Although the long-term follow-up study of inhaled tobramycin3l and TS137 provided reassuring renal safety data, prolonged aminoglycoside inhalation may still be a risk factor for renal damage. Twelve of 20 patients treated with nebulized gentamicin, 120 mg once or twice daily for a mean (SD) of 872 (473) days, had raised urinary N-acetyl-(,B-D-glucosaminidase (NAG) levels that showed a positive correlation with the cumulative gentamicin dose (P = 0.004).4 These results suggest a straightforward dose-response relationship between inhaled antibiotic treatment and renal damage. Patients who had never inhaled gentamicin or had stopped treatment for at least three months had normal and equivalent urinary NAG levels, suggesting a capacity for reversal of toxic changes on cessation of therapy. However, most patients will continue on life-long aerosolized antibiotic treatment once this is started. Longer studies may show greater or more permanent renal damage. Tobramycin should be used with caution in patients with impaired renal function or ototoxicity.55
Conclusion
Nebulized antibiotic treatments for patients with CF are usually safe. Treatment improves lung function, reduces the need for intravenous antibiotic therapy in patients with chronic P. aeruginosa infection, and successfully eradicates most early infection, with or without concomitant oral antipseudomonal antibiotics. Prolonged treatment does not encourage superinfection with naturally resistant organisms. Higher levels of bacterial resistance to the nebulized drug do not seem to have any clinical impact but remain a concern.
Aerosolized antibiotics as add-on therapy to intravenous antibiotic treatment do not improve clinical results but do result in lower sputum counts of P. aeruginosa. Further studies are needed to determine if there is a role for TSI in the treatment of multiresistant P. aeruginosa or early Bcc infection. Evidence-based recommendations for nebulized antibiotic use in CF can only be made for the role of TSI as suppressive therapy.3'5 Adequately powered trials for other drugs have not been performed, although there is a wealth of clinical experience with nebulized colistin in European CF centres. Negative aspects of treatment include the time needed for proper administration of the nebulized drug (20 to 25 hours per month for TSI) resulting in adherence problems,56 and the expense, especially for TSIP6. Nonetheless, new delivery systems may reduce nebulization times57 and the efficacy of nebulized antibiotic therapy may allow reductions in other therapies that offset the increased treatment costs.58 '59 
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